Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment

Amit Khatri, Rajeev M. Menon, Thomas C. Marbury, Eric J. Lawitz, Thomas J. Podsadecki, Victoria M. Mullally, Bifeng Ding, Walid M. Awni, Barry M. Bernstein, Sandeep Dutta

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Background & Aims Paritaprevir, ombitasvir, and dasabuvir are direct-acting antivirals for treatment of chronic hepatitis C virus (HCV) infection. The aim of this study was to characterize the effects of mild, moderate, and severe hepatic impairment on the pharmacokinetics of these drugs. Methods HCV-negative subjects with normal hepatic function (n = 7) or mild (Child-Pugh A, n = 6), moderate (Child-Pugh B, n = 6), or severe (Child-Pugh C, n = 5) hepatic impairment received a single-dose of the combination of paritaprevir plus ritonavir (paritaprevir/r, 200/100 mg), ombitasvir (25 mg), and dasabuvir (400 mg). Plasma samples were collected through 144 hours after administration for pharmacokinetic assessments. Results Paritaprevir, ombitasvir, dasabuvir, and ritonavir exposures (maximal plasma concentration, Cmax, and area under the concentration-time curve, AUC) were minimally affected in subjects with mild or moderate hepatic impairment. Differences in exposures between healthy controls and subjects with mild or moderate hepatic impairment were less than 35%, except for 62% higher paritaprevir AUC in subjects with moderate hepatic impairment. Paritaprevir and dasabuvir AUC were significantly higher in subjects with severe hepatic impairment (950% and 325%, respectively). However, ombitasvir AUC was 54% lower and ritonavir AUC was comparable. Adverse events included eye stye, insomnia, and pain from an infiltrated intravenous line. Conclusions The changes observed in paritaprevir, ritonavir, ombitasvir, and dasabuvir exposures in subjects with mild or moderate hepatic impairment do not necessitate dose adjustment. Subjects with severe hepatic impairment had substantially higher paritaprevir and dasabuvir exposures.

Original languageEnglish (US)
Pages (from-to)805-812
Number of pages8
JournalJournal of Hepatology
Volume63
Issue number4
DOIs
StatePublished - Oct 1 2015

Keywords

  • Chronic hepatitis C
  • Dasabuvir
  • Direct-acting antiviral agents
  • Hepatic impairment
  • Ombitasvir
  • Paritaprevir
  • Pharmacokinetics
  • Ritonavir

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment'. Together they form a unique fingerprint.

  • Cite this

    Khatri, A., Menon, R. M., Marbury, T. C., Lawitz, E. J., Podsadecki, T. J., Mullally, V. M., Ding, B., Awni, W. M., Bernstein, B. M., & Dutta, S. (2015). Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. Journal of Hepatology, 63(4), 805-812. https://doi.org/10.1016/j.jhep.2015.05.029